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Abstract INTRODUCTION: An accumulation of genetic alterations forming the field of can-
cerization is an important event for the transformation from normal to cancer cell 
in multistep carcinogenesis. Histopathologically healthy tumor adjacent tissue 
might be considered as a cancerization field which is typified by genetic changes 
required for the development of cancer. Metallothionein (MT) is considered to be 
a protective and anti-apoptotic protein. The aim of our study was to evaluate the 
MT expression in head and neck squamous cells carcinoma and breast adenocar-
cinoma and their histologically healthy adjacent tissue. Materials and Methods: 
We have sampled 29 tissue samples in total derived from head and neck cancers 
and 29 samples of their clear surgical margins, 33 breast adenocarcinomas and 33 
clear surgical margins. Antibody recognizing MT-1 was used for immunohisto-
chemical analysis. 
RESULTS: MT expression was revealed in 85,7% of head and neck cancers and 
94% of breast adenocarcinomas. It was found in all tumor adjacent tissue. MT 
expression was statistically significantly higher in tumor adjacent tissue than in 
cancer tissue in cases with the presence of lymph node metastases in both, breast 
adenocarcinoma and head and neck squamous cell carcinoma. Generally stroma 
seems to respond to the presence of cancer by the expression of MT, even in tis-
sues which normally do not express MT. 
CONCLUSIONS: MT might be a normal or protective reaction of healthy adjacent 
tissue to the presence of tumor. 
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Introduction
An accumulation of genetic alterations forming 
the field of cancerization is an important event for the 
transformation from normal to cancer cell in multistep 
carcinogenesis. Genetically altered cells from expand-
ing fields are identified both in head and neck and 
breast cancers [1,2,3]. Molecular factors generated in 
this contaminated tissue might be responsible for the 
elevated risk of cancer recurrence [4]. The potential of 
molecular diagnosis using mutations in the p53 gene 
as a tumor specific marker has been proven for the 
detection of occult cells clonally related to the tumor in 
surgical margins [5]. Head and neck cancer is the sixth 
most common cancer in the world. It is characterized 
by high recurrence rate or the occurrence of second 
primary tumors within upper respiratory tract mucosa, 
which is estimated at about 10–30% of surgically dis-
sected tumors, independently of the histopathologically 
clear surgical margins [4,6]. Breast cancer is the most 
common cancer in women in developed countries. It 
was suggested that each breast cancer seems to have 
its own, unique pattern of genetic changes caused by 
a complicated interaction of accumulating genetic 
predisposing factors with somatic changes [7]. Some of 
the invasive breast cancers may have developed directly 
from morphologically normal epithelium, not only 
from ductal carcinoma in situ. Thus, at least some of 
the genetic changes found in the invasive cancers may 
be present in the tumor-adjacent normal tissue [5,8,9].
Histopathologically healthy tumor adjacent tissue 
might be considered as a cancerization field which pos-
sesses genetic alterations required for the development 
of cancer [10]. It is also suspected that single tumor cells 
clonally originating from primary cancer might migrate 
creating micrometastasis [5]. Occult tumor cells can 
also be found in healthy tumor adjacent tissue, and are 
not detected by current diagnostic procedures. Bren-
nan and Partridge identified mutated p53 in healthy 
margins of head and neck cancer, and the p53 presence 
was related to more frequent recurrence of the disease 
and lower survival rate [5,10]. 
Metallothionein (MT) is a low-molecular weight 
(61 amino acids) cysteine rich metal-binding protein 
with functional roles in cell growth, repair and dif-
ferentiation [11]. The MT-1 and MT-2 isoforms have 
been extensively studied, and are believed to serve an 
important role in the homeostasis of essential metals 
such as Zn+2 or Cu+2, during growth and development, 
as well as in the detoxification of heavy metals such as 
Cd+2 and Hg+2. MT could cause the deregulation of 
zinc finger transcription factors as well as other zinc-
-requiring proteins. The resulting of zinc-depleted state 
of the cell, can be implicated in the generation of genetic 
instability necessary for breast tumor progression [12]. 
The pro or anti apoptotic role of MT is somehow con-
flicting depending on studies but in most cases MT is 
considered as a protective and an anti-apoptotic protein 
[13,14]. MT is mainly a cytoplasmic protein although it 
is also detected in nucleus of cells in fetal or early neo-
natal period [14]. MT immunoreactivity was prominent 
in nasopharyngeal cancer tissue, presenting a nuclear 
pattern of staining being inversely correlated with apop-
totic index [15]. It is also known that perinuclear MT 
localization is important for protective function of MT 
against DNA damage and apoptosis induced by external 
stress stimuli [11,14]. According to this study it was 
suggested that MT overexpression might protect tumor 
cells from entering apoptotic process and therefore to 
contribute to tumor expansion.
Cancer cells and clear surgical margin exert an effect 
on each other, and the environmental response probably 
participates in the process of tumor growth.
The aim of our study was to evaluate the MT expres-
sion in two histologically different tumors, head and 
neck squamous cell carcinomas and breast adenocarci-
nomas, and their histologically healthy adjacent tissue. 
Materials and Methods
Group of patients
In all cases patients’ consent was obtained. The 
approval for the research program from the Ethical 
Committee of the Jagiellonian University in Krakow: 
KBET/379/13/2003 was also granted. The patients in 
this study were randomly selected. Surgically removed 
material was evaluated to determine histological type 
and metastases of the lymph nodes using histological 
methods in the Department of Pathomorphology of the 
Jagiellonian University. The clear surgical margin was 
defined as 1cm2 area of tumor adjacent tissue micro-
scopically free of neoplasmatic texture. The surgical 
resection line was macroscopically and histological free 
from cancer texture. All patients with head and neck 
and breast cancer in this study had undergone surgery 
between March 2003 and December 2003 at the Depart-
ment of Otolaryngology and Head and Neck Surgery 
and in First Surgery Department of the Jagiellonian 
University in Krakow.
2.1 Head and neck cancer
We have sampled the total of 58 tissue samples: 29 
samples derived from head and neck squamous cell 
carcinoma, 29 samples from clear surgical margins of 
these tumors and 20 healthy salivary glands. Squamous 
cell carcinoma was recognized in 29 cases of examined 
patients. Men constituted 79.3% (23 patients) of exam-
ined group, while women 20.7% (6 patients). The mean 
age of all patients was 55.3 years, ranging 42–74 years, 
the mean age of men was 59.6 years, the mean age of 
women was 53.8 years. The disease was recognized most 
commonly in 5th decade of life (11 patients), 4th decade 
(9 patients), 6th decade (7 patients) and 7th decade (2 
patients). Clinical staging of 29 invasive tumors was as 
follows: 7 cases in stage II, 7 cases in stage III and 15 
cases in stage IV. The cases were staged according to the 
TNM Classification of Malignant Tumors 5th edition 
1997. Eleven radical laryngectomies were performed, 
7 laryngectomies with partial pharyngectomy and 11 
partial pharyngectomies. Twenty-one patients received 
radiation therapy after operation because of lymph 
node metastases.
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any positivity; 1+ – weak staining in less than 5% of the 
cells; 2+ – moderate – various staining intensity but in 
<50% of the cells, 3+ – strong – staining of more than 
50% of the cells. 
2.4 Statistical analysis
The distribution of subjects was analyzed using Sha-
piro-Wilk’s test. Obtained data and control data were 
compared using Student’s t-test and Mann-Whitney 
test. Significance was accepted at p<0.05.
Results
3.1. Head and neck cancer- squamous cell 
carcinoma
MT expression was identified as a brown, granular 
staining pattern. In cancer cells it was found both in their 
cytoplasm and nuclei (Fig. 1). Stromal cells as well as 
cartilage cells represented an evident cytoplasmic stain-
ing pattern (Fig. 2). Basal cells of stratified epithelium 
represented a nuclear staining pattern (Fig. 3). Lymph 
nodes and tumor infiltrating lymphocytes were MT 
expression negative (Fig.1). Infiltrating inflammatory 
cells were MT expression positive. They represented a 
cytoplasmic staining pattern.
 
3.1.1 MT expression in malignant tissues 
MT expression was identified in 85,7% squamous 
cell carcinomas, while 4 squamous cell carcinoma 
specimens were MT expression negative. Cancer cells 
in the center of the nests were MT expression nega-
tive, while peripherally located cells strongly expressed 
MT. Most of them represented an evident cytoplasmic 
staining pattern but single cells demonstrated nuclear 
pattern of staining (Fig. 4).
3.1.2 MT expression in healthy tissues
Basal cells of stratified squamous cell epithelium 
expressed MT in 44,8% of cases. MT expression was 
identified in healthy stromal cells of tumor adjacent 
tissues. All stromal specimens, mainly composed of 
spindle-shaped fibroblasts, expressed MT. MT stromal 
expression was detected even in cases in which cancer 
specimens did not show MT expression. All salivary 
glands were MT expression negative. We observed 
an intense MT expression at the border of cancer and 
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2.2 Breast cancer
The study group consisted of 33 patients with breast 
cancer. All women underwent mastectomy with axillary 
lymphadenectomy in the First General Surgery Depart-
ment of the Jagiellonian University. The women’s age 
ranged between 34–79 years (mean age – 61 years). In 
each case invasive carcinoma was identified. In all cases 
surgical material was obtained after modified radical 
amputation of the breast with the use of Patey’s method 
with simultaneous removal of axillary lymph nodes. 
Surgical material was fixed in 10% buffered formalin. 
Then tissue was embedded in paraffin and stained with 
hematoxylin and eosin. Each specimen was inspected 
to specify tumor size and a number of lymph nodes 
obtained for the study. Microscopic examination was 
performed to identify histological type and grade 
of invasive ductal carcinoma, the presence of vessel 
invasion and tumor metastases to the lymph nodes. 
Histological grades of invasive carcinoma were diag-
nosed according to Bloom and Richardson classifica-
tion modified by Elston and Ellis, recommended by 
the National Coordinating Group for Breast Pathology 
[18,19]. 
2.3 Immunohistochemistry
Immunohistochemical analysis was performed in 
the Pathomorphology Department of the Jagiellonian 
University. In all immunohistochemical stainings Envi-
sion method was applied using Dako Autostainer, so 
the procedure was the same besides single steps (anti-
gen unmasking, where appropriate, antibody dilutions, 
incubation period). Five-µm slides were deparaffinized, 
rehydrated and rinsed 5 times in distilled water. Endog-
enous peroxidase activity was blocked by 8-min-incuba-
tion in 3% H2O2 at room temperature. The slides were 
then rinsed and immersed in boiling citrate buffer (pH 
6.0) in a microwave oven with three changes of buffer for 
5 minutes each. For Metallothionein immunostaining 
the monoclonal mouse antibody ImmunOTM (MP 
Biomedicals, Inc., clone 1A12 in dilution 1:1000) was 
used, without any previous unmasking procedure, with 
60-min-incubation at room temperature. In both cases 
the same specimens were used as a negative control 
with omission of the primary antibody. This antibody 
recognized human MT-1 izoforms. The slides were sub-
sequently rinsed in TBS buffer (pH 7.6) and incubated 
with secondary antibody (DAKO Envision TM+ System 
Labelled Polymer HRP – anti mouse (DAKO, Denmark) 
for 30 minutes at room temperature. Visualization was 
performed using AEC (3-amino-9-ethyl-carbazole) as 
a chromogen (AEC Substrate Chromogen ready-to-use, 
DAKO, Denmark) for 10 minutes at room temperature. 
Sections were counterstained with hematoxylin and 
mounted in glycergel. Immunohistochemical expres-
sion of MT was evaluated without any knowledge on the 
clinicopathologic data. The degree of Metallothionein 
positivity was quantified as the percentage of MT-posi-
tive cells in the tissue section, done in at least 5 high 
power fields (usually at least 150 cells were counted). 
Only cytoplasmic staining was evaluated as: 0 – lack of 
Figure 1. Demonstrates MT expression in head and neck cancer 
and clear surgical margin. Cancer cells (vertical arrow), were MT 
expression positive (A) or negative (B), represented a nuclear 
and cytoplasmic staining pattern. Stroma expressed MT in both 
cases (horizontal arrow). Lymphocytes (double arrow) were MT 
immunoreactivity negative. 
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stroma, both in cancer and stroma. It appeared that 
tumor induced MT expression in adjacent healthy 
stroma (Fig. 5). Strong MT immunoreactivity was also 
identified in healthy cartilage in the direct cancer vicin-
ity, while cartilages in other regions of tissue slides, dis-
tant from cancer were MT expression negative (Fig. 2).
3.1.3a MT expression in cancer and tumor adjacent 
tissue and clinicopathological features
MT expression in head and neck cancer and its clear 
surgical margin with respect to the presence of lymph 
node metastases is presented in Table 1. 
MT immunoreactivity was significantly higher in 
tumor adjacent healthy tissue than in cancer tissue, 
in cases with the presence of lymph node metastases. 
Higher MT immunoreactivity in tumor adjacent healthy 
tissue than in cancer was identified in poorly differenti-
ated tumors than in moderately differentiated ones. 
3.1.3b Independent analysis of MT expression in 
cancer and adjacent healthy tissue
No significant differences were found in MT 
immunoreactivity in tumor cells according to cancer 
differentiation in moderately (G2) and poorly (G3) 
differentiated tumors, although MT expression was 
higher in G2 tumors (p=0.7). Similarly, no significant 
differences in MT immunoreactivity in tumor adjacent 
healthy tissue were observed with respect to cancer cells 
differentiation. Still MT immunoreactivity in tumor 
adjacent tissue was higher in G2 tumors stroma than 
in G3 (p=0.4). 
Significantly higher MT immunoreactivity in cancer 
samples was found in cases with the presence of lymph 
node metastases than in cases without metastases 
(p=0.03). Also higher MT immunoreactivity was iden-
tified in tumor adjacent healthy tissue in cases with 
the presence of lymph node metastases than in cases 
without metastases (p=0.1). 
Table 1. Demonstrates the changes of MT expression in head and neck cancer and its clear surgical margin with respect to the 
presence of lymph node metastases.
 Metallothionein expression 0* 1* 2* 3* p-value
Head and neck cancer Cancer expression (n=13) 15(2) 39(5) 39(5) 7(1)
tissue, N0 status (n=13) Clear surgical margin expression (n=13) - 93(12) 7(1) -
Head and neck cancer Cancer expression (n=16) 19(3) 68(11) 13(2) -
tissue, N1,N2 status (n=16) Clear surgical margin expression (n=16) - 56(9) 31(5) 13(2)
0.32
0.046
Figure 3. Demonstrates MT expression in normal head and neck 
mucosa (stratified squamous epithelium), where it is expressed 
by basal and parabasal dividing cells. 
Table 2. Immunohistochemical analysis of Metallothionein expression in breast cancer tissue
 Metallothionein expression 0* 1* 2* 3* p-value
Breast cancer tissue, Cancer expression (n=15) 6 (1) 33 (5) 49 (7) 12 (2)
N0 status (n=15) Clear surgical margin expression (n=15) - 12 (2) 33 (5) 55 (8)
Breast cancer tissue  Cancer expression (n=18) 5.5 (1) 27.5 (5) 44 (8) 23 (4)
N1,N2 status (n=18) Clear surgical margin expression (n=18) - 5.5 (1) 11 (2) 83.5 (15)
*All figures refer to percentage of samples
0.01
0.0003
Figure 2. Presents head and neck cancer (vertical arrow) with 
healthy adjacent tissue, stroma and cartilage. Healthy cartilage 
expressed MT (triangle) when it adjusted to tumor tissue, in other 
regions, which were distant from tumor cartilage did not express 
MT. Healthy tumor adjacent tissue represented an evident 
cytoplasmic staining pattern (horizontal arrow). 
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3.2 Breast cancer-adenocarcinoma 
MT expression represented brown, granular stain-
ing pattern, and it was present in cancer and in stromal 
cells as well as in myoepithelial and normal glandular 
epithelium cells, both nuclear and cytoplasmic ones. 
Tumor infiltrating lymphocytes were MT expression 
negative (Fig. 6).
3.2.1 MT expression in malignant tissues 
MT expression was revealed in 94% of cancer tissue 
samples. The MT staining pattern differed according to 
the intensity of MT expression. Cytoplasmic staining 
pattern was predominantly detected in cases of weak 
(+1) intensity of MT expression. In cases of moderate or 
strong intensity of expression, nuclear staining pattern 
was more frequently recognized than cytoplasmic. In 
cancer nests MT expression was stronger in peripher-
Figure 4. Presents MT immunoreactivity in head and neck 
cancer nests. Immunoreactivity is growing from the center to the 
peripheral part. 
A -  The intensity of immunoreactivity is negative in the center 
and positive in the peripheral part. 
B -  The intensity of staining is growing from moderate in the 
center to strong in the peripheral part of the nest; staining 
pattern is cytoplasmic and nuclear.
Figure 5. Positive MT reactivity in stroma (vertical arrow) and 
weak MT reactivity in head and neck cancer nests (horizontal 
arrow). 
Figure 6. MT expression in breast cancer cells (horizontal 
arrow) represented brown, granular staining pattern, and in 
stromal cells as well as myoepithelial and normal glandular 
epithelium cells both nuclear and cytoplasmic (vertical arrow). 
MT expression was higher in breast cancer tissue than in healthy 
tumor adjacent tissue (A, B) and in others MT expression was 
higher in healthy adjacent tissue than in cancer (C,D). MT 
immunoreactivity was higher in peripherally located cells of 
cancer nests than in the center of the nests (A) and higher in the 
neighborhood of MT positive normal glands (B).
Figure 7. MT expression in breast cancer (horizontal arrow) 
and in normal breast glands (vertical arrow): myoepithelial 
cells and glandular epithelium represented both nuclear and 
cytoplasmic staining pattern. 
Figure 8. MT expression in breast cancer (horizontal arrow) 
and in normal breast glands (vertical arrow) and myoepithelial 
cells (vertical arrow). Myoepithelial MT positive cells were 
detected in tumor adjacent healthy vascular wall (double arrow). 
Healthy gland cells in the tumor neighborhood express MT, the 
immunoreactivity decreases from the tumor adjacent cells to the 
gland’s lumen. 
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ally located cells than in cells in the center of the nest 
(Fig. 6).
3.2.2 MT expression in healthy tissues
MT was identified in all samples derived from 
tumor adjacent healthy tissue. MT immunoreactivity 
decreased with the growing distance from tumor. The 
immunoreactivity of MT in tumor adjacent healthy 
tissue was represented predominantly by myoepithelial 
and epithelial cells of the glands. In myoepithelial cells 
both cytoplasmic and nuclear type of staining was 
observed, but cytoplasmic staining dominated, whereas 
glandular epithelium showed nuclear staining rather 
than cytoplasmic staining pattern (Fig. 7). 
3.2.3 MT expression in cancer with respect to 
clinicopathological features 
MT expression was evaluated in cancer and healthy 
tumor adjacent tissue and analyzed as regards the pres-
ence of lymph node metastases and tumor grading. 
3.2.3a Comparison of MT expression in cancer 
and adjacent healthy tissue
The expression of MT with respect to the presence of 
lymph node metastases is presented in Table 2. 
MT immunoreactivity was statistically significantly 
higher in tumor adjacent healthy tissue than in cancer 
tissue in cases with the presence of lymph node metasta-
ses. Also significantly higher MT immunoreactivity was 
observed in cases without the presence of lymph node 
metastases, but the difference was not that pronounced, 
as in the group of the patients with the presence of 
lymph node metastases. 
The differentiation of breast cancer was evaluated 
according to Bloom classification: 13% of cases rep-
resented Bloom-1 stage, in 54% Bloom-2 stage, and 
in 33% Blooom-3 stage were recognized. Higher MT 
immunoreactivity in tumor adjacent healthy tissue 
than in cancer was identified in all types of tumor dif-
ferentiation. Breast cancer tumors classified as Bloom-2 
group represented significantly higher MT expression 
in tumor adjacent tissue than in cancer (p=0.017). 
In Bloom-1 group MT immunoreactivity was a little 
higher, while in Bloom-3 it was on the verge of statisti-
cal significance (p=0.08). 
3.2.3b Independent analysis of MT expression in 
cancer and adjacent healthy tissue
No differences were found in MT immunoreactivity 
in tumor cells according to the cancer differentiation 
in Bloom-2 and Bloom-3 cancers. No differences in 
MT immunoreactivity in tumor adjacent healthy tissue 
were observed according to cancer cells differentiation. 
Higher MT immunoreactivity in cancer samples was 
found in cases with the presence of lymph node metas-
tases than in cases without metastases (p=0.68). Also 
higher MT expression was identified in tumor adjacent 
healthy tissue in cases with the presence of lymph node 
metastases than in cases without metastases (p=0.08). 
The analysis of correlation between the presence and 
number of lymph node metastases and the expression of 
MT correlation coefficient was 0.3 and revealed statisti-
cally significant correlation (p=0.045). MT expression 
in cancer did not correlate with the presence of lymph 
node metastases. 
Discussion
MT expression in tumor adjacent tissue of exam-
ined cancers (breast adenocarcinoma and head and 
neck squamous cells carcinoma) in comparison to MT 
expression in cancer tissue was significantly higher in 
cases with the presence of lymph node metastases in 
comparison to cancers without the presence of lymph 
node metastases (Table 1,2). 
MT expression is recognized as a useful prog-
nostic tool, especially in invasive ductal carcinoma 
[20]. In head and neck cancer high MT-1 and MT-2 
immunoreactivity correlated with increased local and 
regional recurrence, resulting in poor prognosis [21]. 
Contrary to these findings, the analysis of MT-1 and 
MT-2 expression performed in oesophageal cancer 
revealed little impact on the outcome [22]. Although 
MT-3 expression analysis in infiltrating ductal breast 
carcinoma indicated that MT-3 positive cells were more 
frequent in patients with bad outcome [12]. Both in the 
studied head and neck and breast cancers the connec-
tion between MT expression in healthy tumor adjacent 
tissue and the presence of lymph node metastases was 
noted. The presence of lymph node metastases is a poor 
prognostic factor. Consequently MT expression in clear 
surgical margin indicates a worse prognosis.
Immunohistochemical studies have demonstrated 
MT to be present in the cytoplasm and nuclei of several 
physiological tissues and, besides, to be expressed at 
elevated levels in a variety of tumor cells. In normal 
oral squamous cell epithelium MT was located only in 
the basal-parabasal dividing cells [23]. In our study MT 
expression was localized in the nuclei of basal cells of 
normal epithelium of head and neck (Fig. 3), which is 
understandable because these cells are responsible for 
proliferation and renewal of the epithelium. Normal 
stromal cells and inflammatory cells represented an 
evident cytoplasmic staining pattern. Healthy salivary 
glands were chosen as a control tissue. MT expression 
was reported to be intense in pleomorphic adenoma 
and adenoid cystic carcinoma, and was present in duct 
epithelial and myoepithelial cells [14,24]. In our study 
healthy salivary glands in tumor adjacent tissue of head 
and neck cancer were MT expression negative. However, 
normal breast glands adjacent to breast cancer were MT 
positive and nuclear type of staining dominated over 
the cytoplasmic staining pattern in these cells. MT cyto-
plasmic staining pattern was also observed in normal 
myoepithelial cells adjacent to breast cancer (Fig. 7). 
Both breast cancer and head and neck cancer repre-
sented a cytoplasmic and nuclear staining pattern. This 
remains in concordance with oral cavity squamous cell 
carcinomas, in which MT positivity was observed in the 
nests of well-differentiated carcinomas in the peripher-
ally located tumoral cells, but not in the center of the 
nests, where increased rate of apoptosis was found [15]. 
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Less differentiated areas presented MT positivity, but 
little apoptosis, suggesting that MT, possibly due to its 
chelating properties, might contribute to delaying cells 
entering apoptosis both in normal epithelium near the 
base and in less differentiated regions of tongue squa-
mous cell carcinoma [23]. Similarly, in our research the 
cells located in the center of head and neck squamous 
cell carcinomas nests did not express MT, while periph-
erally located cells strongly expressed MT (Fig. 4).
Although Jin et al. demonstrated both nuclear and 
cytoplasmic staining patterns type of MT-1 and MT-2 
in breast cancer [24,25,26], in our study predominant 
nuclear MT staining pattern was observed in cancers of 
strong and moderate MT immunoreactivity, while pre-
dominant cytoplasmic staining pattern was observed 
in weak MT tumors [25,26]. In breast cancer, as well as 
in head and neck cancer, MT expression was higher in 
peripherally located cells in cancer nests (Fig. 4, 6). MT-
1 and MT-2 immunohistochemical analysis in breast 
cancer was significantly higher in poorly differentiated 
tumors in comparison to moderately differentiated 
tumors [25,26]. In the present study, we did not observe 
any differences in MT expression with respect to cancer 
grade. However, when the comparison of MT expres-
sion in cancer and tumor adjacent tissue of each case 
was considered, it turned out that significantly higher 
MT expression was detected in tumor adjacent healthy 
tissue in comparison to breast cancer classified as 
Bloom-2 tumors and Bloom-3 tumors. However, the 
difference was lower in Bloom-3 tumors. This might 
indicate that cancer cells which are less differentiated 
in Bloom-3 are not properly recognized and exert weak 
effect on the adjacent tissue, which might let the single 
occult tumor cell spread without a significant trace in 
healthy adjacent tissue. 
In the current study it appeared that healthy tumor 
adjacent tissue responded to tumor growth by the 
expression of MT. The presence of MT expression was 
revealed in all healthy tumor adjacent samples, even in 
those in which cancer cells did not express MT (Fig. 5). 
We also observed that healthy cartilage in the direct 
head and neck tumor vicinity expressed MT while 
healthy cartilage distant from tumor did not express 
MT. In addition, in breast cancer MT positive cells 
were detected in tumor adjacent healthy vascular wall. 
Healthy gland cells in the tumor vicinity also expressed 
MT. The immunoreactivity decreased from the tumor 
adjacent cells to the gland’s lumen (Fig. 8).This might 
suggest that cancer cell migrating from the tumor evokes 
the MT expression in adjacent cells. It might therefore 
be speculated that healthy adjacent tissue responded 
to cancer growth by MT expression, which high repre-
sentation is related to accepted poor prognostic factors 
like the presence of lymph node metastases. Myoepi-
thelial cells in tumor adjacent healthy tissue might be 
responsible for the proliferation of adjacent tumor 
cells by, for example secretion of growth factors [27]. 
MT overexpression in tumor adjacent healthy tissue 
in our study might confirm this possible participation 
of MT in maturation and proliferation. This could be 
also a reaction to the factors secreted by tumor cells, or 
tumor cell fragments which might be represented by 
apoptotic bodies, or tumor cell derived microvesicles 
(TMV). It was demonstrated that TMV might modulate 
biological function of tumor infiltrating monocytes and 
lymphocytes. In 1972 JF Kerr described apoptosis and 
indicated the possible usage of apoptotic cell fragments 
by normal epithelial cells and neoplasmatic cells [28]. 
This phenomenon seems also to be very important 
in the light of multistep genetic carcinogenesis [3]. 
Apoptotic bodies include normal cell organelles, mRNA 
and DNA. It was also demonstrated that mRNA and 
DNA are separately packed in apoptotic bodies dur-
ing apoptosis [29]. DNA amplification derived from 
apoptotic body was also confirmed [30,31]. Garcia 
showed that mutated DNA originating from apoptotic 
body may create a genometastasis [32,33]. MT expres-
sion might also result from the normal cell exposure 
to cancer and cancer derived factors like DNA or cell 
fragments. Klimek’s theory concerning cancerogenesis 
posits the existence of an area adjacent to tumor exposed 
to cancerous transformation and defines this area as a 
dysypatogenic structure comprising the cells that have 
already entered the neoplastic transformation [34,35]. 
Our findings remain in compliance with this theory, the 
expression of Metallothionein in tumor adjacent histo-
pathologically healthy tissue might be the manifestation 
of already present alterations in these cells, which have 
not yet developed phenotypic changes. 
In conclusion, this finding might suggest, that 
MT expression is a normal or protective reaction of 
healthy adjacent tissue. We posit that MT expression 
in healthy stroma is induced by spreading tumor cells 
leaving a “snailmark” delaying apoptosis and inducing 
immortalization of these cells, which might presage the 
development of cancer.
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